Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.54 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357925 | 1.00 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15816901 | 0.91 | PIK3CD (0.47) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16133576 | 0.91 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15816899 | 0.91 | PIK3CD (0.47) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15870127 | 0.90 | PIK3CD (0.45) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15817058 | 0.90 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15817059 | 0.90 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL22039327 | 0.89 | PIK3R2 (0.51) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL18188636 | 0.89 | PIK3R2 (0.51) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15816856 | 0.88 | PIK3CB (0.52) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10954199-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10414737-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190031626-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2005113554-A2 | METHOD OF PREPARING 3-PHENYL-2-[9H-PURIN-6-YLAMINO)-METHYL]-3H-QUINAZOLIN-4-ONE AND SUBSTITUTED AND RELATED COMPOUNDS | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CG 4/4885PIK3CD 1/4885PIK3CB 5/4885 |
| US-10414737-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | PIK3CB, PIK3CA, PIP4K2B | PIK3CG 16/4885PIK3CD 12/4885PIK3CB 1/4885 |
| US-20190031626-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CB, PIK3CA, PIP4K2B | PIK3CG 16/4885PIK3CD 12/4885PIK3CB 1/4885 |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CG 4/4885PIK3CD 1/4885PIK3CB 5/4885 |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | PIK3CG 4/4885PIK3CD 1/4885PIK3CB 5/4885 |
| US-10954199-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | PIK3CB, PIK3CA, PIP4K2B | PIK3CG 16/4885PIK3CD 12/4885PIK3CB 1/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | PIK3CG 4/4885PIK3CD 1/4885PIK3CB 5/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CG 4/4885PIK3CD 1/4885PIK3CB 5/4885 |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | PIK3CD, PIK3CA, PIK3CB | PIK3CG 4/4885PIK3CD 1/4885PIK3CB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.